Dementia Clinical Trials | NeuroTrials.ai

Can a tau aggregation inhibitor slow cognitive decline in MCI and mild-to-moderate Alzheimer disease?

TRx-237-039

Hydromethylthionine mesylate for MCI and mild-to-moderate Alzheimer disease: a phase 3 randomized trial

JPAD · 2026

Bottom Line: HMTM 16mg/day failed its primary endpoint at 52 weeks but showed significant cognitive benefit in MCI patients at 78 and 104 weeks, suggesting delayed tau-targeted treatment effects.

ALZHEIMER'S DISEASE 5

Does oral valiltramiprosate slow clinical decline and brain atrophy in APOE4/4 homozygotes with early Alzheimer's disease without causing ARIA?

APOLLOE4

2025

Drugs

Does dulaglutide reduce plasma ADRD biomarkers (NfL, p-tau217, GFAP) and substantive cognitive impairment in adults with type 2 diabetes?

REWIND-Dementia

2026

Alzheimer's & Dementia

Does oral S-adenosyl methionine (SAMe) 400 mg daily for 6 months reduce plasma p-tau217 in patients with MCI or dementia due to Alzheimer's disease?

SAMe-AD

2026

Alzheimer's & Dementia

Can a subcutaneous formulation of lecanemab — administered by vial or autoinjector — deliver comparable exposure and predicted efficacy to the intravenous formulation in healthy adults?

Subcutaneous Lecanemab

2025

Alzheimer's & Dementia

Can a modified donanemab titration schedule reduce ARIA-E risk without sacrificing amyloid clearance in early Alzheimer's disease?

TRAILBLAZER-ALZ 6

2025

Alzheimer's & Dementia

DISEASE-MODIFYING THERAPY / DRUG REPURPOSING 1

ELAD

2026

Liraglutide 1.8 mg SC daily for 52 weeks did NOT reduce decline in cerebral glucose metabolism (primary outcome) in mild-to-moderate Alzheimer's disease, but showed an exploratory cognitive benefit on...

Nature Medicine

IMMUNOTHERAPY 1

Can crenezumab, started before symptom onset, prevent or delay cognitive decline in cognitively unimpaired PSEN1 Glu280Ala mutation carriers predestined to develop autosomal-dominant Alzheimer's disease?

API ADAD Colombia

2026

Lancet Neurology

DISEASE MODIFICATION (MCI) 1

Does low-dose lithium slow cognitive decline and preserve brain volume in adults with mild cognitive impairment?

LATTICE

2026

JAMA Neurology

BIOMARKERS 3

Can plasma p-tau217 serve as a reliable endpoint for Alzheimer disease clinical trials?

p-tau217 Endpoint

2026

Plasma p-tau217 as a Clinical Trial Endpoint for Alzheimer Disease

Neurology

Can plasma p-tau217 trajectories predict when a cognitively normal person will develop symptomatic Alzheimer disease?

p-tau217 Clocks

2026

Plasma p-tau217 Clocks for Predicting Onset of Alzheimer Disease

Nature Medicine

Can an automated plasma p-tau217 assay accurately diagnose Alzheimer disease pathology in clinical practice?

p-tau217 Lumipulse

2025

Plasma p-tau217 Lumipulse Assay for Alzheimer Disease Diagnosis

Nature Medicine

THERAPEUTICS 1

Can a tau aggregation inhibitor slow cognitive decline in MCI and mild-to-moderate Alzheimer disease?

TRx-237-039

2026

Hydromethylthionine Mesylate (HMTM) for MCI and Mild-to-Moderate Alzheimer Disease

JPAD

BIOMARKER 1

Can plasma %p-tau217 clock models estimate the age at biomarker positivity and predict when cognitively unimpaired individuals will develop symptomatic Alzheimer disease?

Plasma p-tau217 Clock

2026

Nature Medicine

DIAGNOSTIC 1

Does the fully automated Lumipulse plasma p-tau217 immunoassay accurately detect Alzheimer disease pathology in symptomatic patients across diverse clinical settings using predefined biomarker cutoffs?

Plasma p-tau217 Validation

2025

Nature Medicine